Leonid Cherkassky
Overview
Explore the profile of Leonid Cherkassky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagerty B, Fekrmandi F, Schneider T, Fountzilas C, Stiles Z, Kukar M, et al.
J Surg Oncol
. 2024 Aug;
130(5):1014-1022.
PMID: 39155683
Background And Objectives: Patients with localized pancreatic adenocarcinoma who do not respond to neoadjuvant therapy present a challenge. We sought to define the characteristics and outcomes of those patients to...
2.
Benesch M, Cherkassky L, Nurkin S
Ann Surg Oncol
. 2024 May;
31(8):4831-4833.
PMID: 38777897
No abstract available.
3.
Abdelfatah E, Ramos-Santillan V, Cherkassky L, Cianchetti K, Mann G
Ann Surg Oncol
. 2023 Jan;
30(4):2035-2045.
PMID: 36648616
Background: Frailty is a physiologic state that affects perioperative outcomes. Studies evaluating the impact of frailty on long-term oncologic outcomes are limited. This study evaluated perioperative and long-term oncologic outcomes...
4.
Cherkassky L, Oshi M, Abdelfatah E, Wu R, Takabe Y, Yan L, et al.
Am J Cancer Res
. 2022 Aug;
12(7):3099-3110.
PMID: 35968349
Despite low mutational burden, immune checkpoint inhibitors have demonstrated promising results in a significant minority of hepatocellular carcinoma (HCC) patients with advanced disease. We hypothesized that HCC patients with higher...
5.
Cherkassky L, Hou Z, Amador-Molina A, Adusumilli P
Cancer Cell
. 2022 Apr;
40(6):569-574.
PMID: 35487216
The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional...
6.
Cherkassky L, Adusumilli P
Nat Biomed Eng
. 2021 Nov;
5(11):1243-1245.
PMID: 34773102
No abstract available.
7.
Satyananda V, Chouliaras K, Cherkassky L, Schwarz R
J Surg Case Rep
. 2021 Nov;
2021(10):rjab414.
PMID: 34729163
Biliary tract cancers (BTCs) have limited response to systemic therapy and poor prognosis. Immunotherapy in BTCs has been investigated in recent years. Here, we report a case of locally advanced,...
8.
Oshi M, Kim T, Tokumaru Y, Yan L, Matsuyama R, Endo I, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33477315
Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related deaths worldwide. In this study, a total of 749 HCC patients from 5 cohorts...
9.
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser R, Cherkassky L, Chintala N, Adusumilli P
Cancer Cell
. 2019 Nov;
36(5):471-482.
PMID: 31715131
Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an exhausted immune response. However, response rates remain limited, likely secondary to a lack of a tumor-reactive immune infiltrate....
10.
Cherkassky L, DAngelica M
Surg Oncol Clin N Am
. 2019 Sep;
28(4):619-630.
PMID: 31472909
Managing patients with incidental gallbladder cancer requires stratifying patients risk for recurrence and an appreciation for the recurrence patterns characterizing this malignancy. Although standard management includes reresection to remove sites...